NOVO NORDISK A/S Patent applications |
Patent application number | Title | Published |
20160106927 | Drug Delivery Device and System with Pre-Set Dose Feature - A drug delivery device comprises drug expelling means and a drug-filled cartridge, the cartridge comprising an outlet and an axially displaceable piston. The drug expelling means comprises a drive member adapted to engage and axially move the piston to thereby expel an amount of drug from the cartridge through the outlet, and a motor for moving the drive member. The device further comprises a display adapted to display a dose amount to be expelled, communication means allowing dose setting data to be received from an external device, and an electronic controller adapted to store received dose setting data, control the display, and control the motor to move the drive member to thereby expel an amount of drug corresponding to a set dose. | 04-21-2016 |
20160089501 | Frontloaded Drug Delivery Device with Dynamic Axial Stop Feature - Drug delivery device adapted to receive a cartridge and comprising a housing, a front-loaded cartridge holder adapted to receive and hold a cartridge in a loaded position, and stop means adapted to engage a proximal surface of a received cartridge The stop means is actuatable between a receiving state in which the stop means is positioned in a first axial position thereby defining how far proximally a received cartridge can be inserted, and an operational state in which the stop means allows an inserted cartridge to be moved axially to a second more proximal position. | 03-31-2016 |
20160060351 | Use of C5AR Antagonists - C5a and C5aR stimulate the inflammatory response and C5aR antagonist can counteract this function performing as an anti-inflammatory agents. This functionality is considered useful in treatment of inflammatory diseases including auto immune diseases. In addition it has been found that C5a and C5aR have a function in relation to bone homeostasis and remodelling and that C5aR antagonists are useful for treatment of bone damage, such as bone erosion and loss of bone density and for treatment of bone damage and cartilage damage. | 03-03-2016 |
20160039940 | Human CD30 Ligand Antigen Binding Proteins - Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided. | 02-11-2016 |
20160024487 | THROMBIN SENSITIVE COAGULATION FACTOR X MOLECULES - The present invention relates to thrombin sensitive coagulation Factor X (FX), as well as use thereof in medicine. In particular the invention relates to FX molecules comprising 2 to 10 amino acid modifications in the activation peptide N-terminally of the FX “IVGG” motif as well as compositions comprising such molecules and use thereof. Such molecules may be useful in connection with convenient and patient friendly treatment regimens in treatment and prophylaxis of haemophilia. | 01-28-2016 |
20160015903 | Rotary Sensor Module with Axial Switch - Sensor assembly comprising a first rotary sensor part with a plurality of individual electrically conducting sensor areas arranged in a pattern, a second rotary sensor part arranged rotationally relative to the first portion, the second part comprising a plurality of contact structures adapted to be in contact with conducting sensor areas on the first sensor rotary part. The contact structures are configured to engage and connect different sensor areas as the first and second part of the rotary sensor rotate relative to each, the created connections being indicative of a rotational position between the first and second portions. One of the contact structures is an actuatable contact structure being axially moveable relative to the first portion and having a connected position in which the actuatable contact structure is in contact with a sensor area and a disconnected position in which the actuatable contact structure is not in contact with a sensor area. | 01-21-2016 |
20160000884 | Liquid Factor VIII Formulations - The invention is directed to a liquid, aqueous formulation of coagulation Factor VIII, comprising a Factor VIII molecule, a calcium salt in a concentration of more than 10 mM, and a saccharide and/or polyol in a concentration of at least 100 mM, wherein the formulation has a pH from 5.5-7.5. The invention furthermore provides a method for optimising a liquid formulation of coagulation Factor VIII, the method comprising the steps of: (i) Providing one or more liquid formulations comprising Factor VIII to be tested; (ii) Adding a protein denaturant to said liquid formulations, and incubating the resulting solutions for a predetermined period of time; (iii) Analysing the incubated solutions of (ii) for the presence of dissociated Factor VIII; and (iv) Selecting one or more formulation(s) having a desired low level of dissociated Factor VIII. | 01-07-2016 |
20150367078 | A Non-Axial Working End-Of Content Mechanism and an Injection Device Comprising the Same - The invention relates to a non-axial working End-of-Content mechanism which is geared by a hypocycloid gearing. The EoC mechanism comprises a first element ( | 12-24-2015 |
20150367077 | Drug Delivery Device with Dose Capturing Module - A drug delivery system is provided comprising drug expelling means adapted to expel a set dose from a drug-filled cartridge, the expelling means comprising a rotational member adapted to rotate relative to a housing and corresponding to a set and/or expelled dose, the system comprising a sensor adapted to detect a set and/or an expelled dose. The sensor comprises a first portion mounted to and rotating with the rotational member, and a second portion comprising a second rotary sensor part mounted non-rotationally relative to the housing. The first portion comprises electronic circuitry, and a first rotary sensor part, and the second portion comprises a second rotary sensor part mounted non-rotationally relative to the housing. The first and second rotary sensor parts rotate relative to each other during set- ting and/or expelling of a dose of drug. | 12-24-2015 |
20150335827 | A Needle Device - The invention relates to a needle device which is made from a housing ( | 11-26-2015 |
20150335825 | DRUG DELIVERY DEVICE WITH FRONT LOADING FEATURE - A drug delivery device adapted to receive a cartridge and hold it in a mounted position is provided, comprising a housing, an expelling assembly, and a front-loaded cartridge holder assembly adapted to receive and hold a cartridge in a mounted state. The assembly comprises cartridge holding means actuatable between a receiving state and a holding state, as well as a user operated actuation sleeve being rotationally actuatable relative to the housing between a loading state and an operational state, such that the cartridge holding means is actuated from the receiving state to the holding state when the actuation sleeve is actuated from the loading state to the operational state. The actuation sleeve is configured to enclose at least a portion of a mounted cartridge and is provided with inspection means allowing at least a portion of an enclosed cartridge portion to be visually inspected. | 11-26-2015 |
20150320939 | Injection Device with Integrated Needle Shield - The invention relates to injection device, which device comprises an outer housing ( | 11-12-2015 |
20150239984 | THERAPEUTIC FACTOR VIII ANTIBODIES - The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A. | 08-27-2015 |
20150225710 | Coagulation Factor IX Conjugates - The present invention relates to Factor IX polypeptides conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used—for example—in the treatment or prevention of bleeding disorders such as haemophilia B. | 08-13-2015 |
20150202369 | Spring-Loaded Injection Device with an Injection Button - The present invention relates to a spring-loaded medical injection device for automatically ejecting set doses of a drug having an injection button ( | 07-23-2015 |
20150126442 | INSULIN FORMULATIONS - A stable pharmaceutical formulation containing an insulin derivative can conveniently be prepared by adding glycerol, phenol, m-cresol and zinc ions to it. | 05-07-2015 |
20150088092 | Drug Delivery Device and Method for Detection of End-Of-Dose Condition - Method for detecting an end-of-dose condition in a pressurized system, comprising the steps of (a) providing a system having a fluid-filled variable volume reservoir comprising an elastically deformable portion and an outlet, pressurizing means, and means for detecting a property of the elastically deformable portion which varies with the internal pressure in the reservoir, (b) pressurizing the reservoir to expel a desired amount of fluid by applying a force, thereby deforming the elastically deformable portion, (c) measuring, after the actuating step, a property related to the elastically deformable portion as it regains its initial configuration, (d) comparing a value for the measured property with one or more threshold values, and (e) providing a user with an indication when a given threshold value has been reached, and/or when a given threshold value has not been reached within a given period of time. | 03-26-2015 |
20150066429 | Medical Delivery Device With Regimen Identification Feature - A drug delivery system comprising a controller adapted to detect when a given user-actuated operation being part of the expelling of an amount of drug is performed, record detected operations as a function of time, and estimate, based on recorded operations, time parameters for the detected operations, thereby providing time parameters for a medical regimen on which the detected operations are assumed to be based upon. | 03-05-2015 |
20150038915 | Injection Device with a Sliding Scale - The present invention relates to an injection device for automatic spring driven injection of a liquid drug. The injection device has a dose setting mechanism by which doses of an individual size can be set by a user, and a mechanical dose size display for displaying the size of the set dose. A housing ( | 02-05-2015 |
20150038903 | Safety Needle Assembly - The invention relates to a safety needle assembly for injecting a fluid into a human body comprising a cylindrical housing with a bottom surface supporting a needle cannula and a shield telescopically movable relative to the housing. A spring located within the housing urges the shield in a distal needle covering direction and a locking member also provided inside the housing moves simultaneously with the shield during injection and automatically locks the shield in a position where the sharp end of the needle cannula is concealed thereby irreversible immobilizing the safety needle assembly. | 02-05-2015 |
20150038417 | GLP-1 Agonists - A method for the prevention or treatment of alcoholism and drug addiction comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 agonist. | 02-05-2015 |
20150025475 | Syringe Device - A medical delivery system comprising a container and a coupling mechanism movable between a coupling position wherein distal movement of a drive mechanism is transferred to an actuator, and a non-coupling position wherein distal movement is not transferred to the actuator. Moreover the present invention relates to a dosing assembly for use in the medical delivery system and a container for use in the medical delivery system. Finally, the present invention relates to medical delivery system comprising a dosing assembly having means for preventing a drive stem of the dosing assembly from being moved in a distal direction. | 01-22-2015 |
20150025471 | Automatic injection device with reset feature - The present invention relates to a dose setting and expelling device comprising a drive member and a dose setting mechanism which simultaneously sets a given dose and stores the energy necessary for a subsequently driving the drive member in order to expel a dose of medicine from an injection device. According to the invention the dose setting mechanism allows adjustment in both directions, such that a given set dose can be reduced or cancelled by reversing the input motion, typically by rotating a setting member backwardly, this in contrast to the known devices which either requires an additional release mechanism or which cannot be reversed at all. | 01-22-2015 |
20150025469 | Revolving Needle Magazine - A needle magazine ( | 01-22-2015 |
20140378801 | Medical System Configured to Collect and Transfer Data - A system comprising processor means configured to collect and store data, display means controlled by the processor means, and switch means allowing the system to be set in a display mode or a data transfer mode. When the system is in the display mode the processor means is configured to control the display means to display stored data using user-readable numeric values, and when in data transfer mode the processor means is configured to generate a machine-readable-only visual representation of the stored data, and control the display means to display the machine-readable-only visual representation. | 12-25-2014 |
20140371682 | Adaptive System for Optimizing a Drug Dosage Regimen Over Time - A system for optimizing a patient's basal insulin dosage regimen over time, adapted to determine from blood glucose values whether and by how much to vary a patient's present recommended amount of the insulin-containing drug in order to maintain the patient's future blood glucose level measurements within a predefined range, and wherein a given blood glucose value is disregarded if no patient-actuated operation being indicative of the administration of a dose of an insulin containing drug has been detected in a pre-defined amount of time prior to the determination of the given blood glucose value. | 12-18-2014 |
20140364587 | Dipeptide Comprising a Non-Proteogenic Amino Acid - Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids. | 12-11-2014 |
20140357838 | N-Terminally Modified Insulin Derivatives - The invention is related to novel N-terminally modified insulin derivatives comprising extra disulphide bond(s), pharmaceutical compositions comprising such and methods of making such. | 12-04-2014 |
20140336586 | Drug Filled Delivery Assembly - A drug delivery assembly comprises a housing ( | 11-13-2014 |
20140330212 | Magnetic Time Delay Indicator and an Injection Device Incorporating Such - The present invention relates to a time delay indicator ( | 11-06-2014 |
20140323974 | Injection Pen with Mechanical Dose Display Comprising Large Ciphers - The present invention relates to an injection device ( | 10-30-2014 |
20140303563 | Injection Device with Torsion Spring and Rotatable Display - The present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof. | 10-09-2014 |
20140303083 | GLP-1 Derivatives - The invention relates to a derivative of a GLP-1 peptide, which peptide has two Lys residues, namely a first and a second Lys residue, and a maximum of eight amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second Lys residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 15: HOOC—(CH2)x-CO—*, and Chem. 16: HOOC—C6H4-O—(CH2)y-CO—*, in which x is an integer in the range of 10-16, and y is an integer in the range of 8-12; and the linker comprises a first linker element *—NH—CH(CH2OH)—CO—*. A preferred linker is g Glu-Ser-Ser-Gly-Ser-Ser-Gly (SEQ ID NO: 2). The derivative of the invention has a very good potency, and a very good binding to the GLP-1 receptor. The invention also relates to the pharmaceutical use of the derivative, for example in the treatment and/or prevention of all forms of diabetes and related diseases. | 10-09-2014 |
20140296131 | Truncated GLP-1 Derivatives and Their Therapeutical Use - The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration. | 10-02-2014 |
20140294853 | ANTAGONISTIC DR3 LIGANDS - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 10-02-2014 |
20140294762 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 10-02-2014 |
20140276598 | INJECTION DEVICE FOR DELIVERING A FIXED DOSE OF LIQUID DRUG - An injection device ( | 09-18-2014 |
20140276450 | Arrangement For Sequential Delivery of Fluid Volumes - The present invention relates to a reservoir unit ( | 09-18-2014 |
20140276381 | Injection Device Comprising an Optical Sensor - The present invention relates to an injection device comprising an optically-based sensor for determining the position or setting of a dose setting member arranged to set a dose to be injected from the injection device. In particular, the present invention relates to an injection device comprising a rotatably mounted member having a plurality of optically coded paths arranged on an outer surface thereof. The rotatably mounted member is operatively connected to the dose setting member and is adapted to rotate with the dose setting member. | 09-18-2014 |
20140257195 | Medical Injection System Comprising a Medical Injection Device and a Dose Limiter Module - The present invention relates to a medical injection system comprising a medical injection device ( | 09-11-2014 |
20140255481 | Pharmaceutical Compositions for Oral Administration of Insulin Peptides - The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such. | 09-11-2014 |
20140249483 | Piston Rod Foot - The invention relates to a medical drug delivery apparatus which comprises a cartridge ( | 09-04-2014 |
20140243761 | Process for Shaping a Needle Cannula - A regular metallic, cylindrical tubular needle cannula ( | 08-28-2014 |
20140243750 | System for Determining Position of Element - System comprising a sensor assembly ( | 08-28-2014 |
20140242057 | CONJUGATED FACTOR VIII MOLECULES - The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules. | 08-28-2014 |
20140234963 | EFFICIENT INDUCTION OF DEFINITIVE ENDODERM FROM PLURIPOTENT STEM CELLS - The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm. | 08-21-2014 |
20140220029 | COMBINED USE OF A MODULATOR OF CD3 AND A GLP-1 COMPOUND - Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound. | 08-07-2014 |
20140206615 | GLP-1 AGONIST AND CARDIOVASCULAR COMPLICATIONS - Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. | 07-24-2014 |
20140206610 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 07-24-2014 |
20140203044 | Electrolytic CIP-Cleaning Process for Removing Impurities from the Inner Surface of a Metallic Container - The invention relates to a novel electrolytic process for removing impurities from the inner surface of a metallic container. The process is particularly useful for cleaning process reactors used for culturing microorganisms, and storage tanks used for storing metabolites formed in the process reactor, as well as containers for dairy products. | 07-24-2014 |
20140200545 | SYSTEM FOR OPTIMIZING A DRUG DOSAGE REGIMEN OVER TIME - A system for optimizing a patient's basal insulin dosage regimen over time, adapted to determine from blood glucose values whether and by how much to vary a patient's present recommended amount of the insulin-containing drug in order to maintain the patient's future blood glucose level measurements within a predefined range, and wherein a given blood glucose value is disregarded if no patient-actuated operation being indicative of the administration of a dose of an insulin containing drug has been detected in a pre-defined amount of time prior to the determination of the given blood glucose value. | 07-17-2014 |
20140200519 | MEDICAL DEVICE HAVING USER FRIENDLY CONTROL INPUT - The present invention relates to a medical delivery comprising a) a housing ( | 07-17-2014 |
20140194826 | DRUG DELIVERY INJECTION PEN WITH ADD-ON DOSE CAPTURING AND DISPLAY MODULE - A drug injector ( | 07-10-2014 |
20140194825 | DRUG DELIVERY INJECTION PEN WITH ADD-ON DOSE CAPTURING AND DISPLAY MODULE - Drug injection device ( | 07-10-2014 |
20140194599 | Anti-Human Interleukin-20 Antibodies - Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders. | 07-10-2014 |
20140193430 | COMPOSITIONS AND METHODS FOR REGULATING NK CELL ACTIVITY - The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects. | 07-10-2014 |
20140188051 | Medical Delivery System with a Rotatable Coding Element - A medical delivery system having a container and a dosing assembly, and wherein one of the container and the dosing assembly comprises a rotatable element adapted to engage the other one of the container and the dosing assembly. | 07-03-2014 |
20140179899 | DOUBLE-ACYLATED GLP-1 DERIVATIVES - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1(7-37), and a maximum of ten amino acid modifications as compared to GLP-1(7-37), wherein the first K residue is designated K | 06-26-2014 |
20140170728 | Factor IX: Remodeling and Glycoconjugation of Factor IX - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 06-19-2014 |
20140170153 | IL-21 EPITOPE AND IL-21 LIGANDS - The present invention relates to IL-21 ligands, such as e.g. antibodies, as well as use thereof. | 06-19-2014 |
20140154230 | Glycopegylated Factor IX - Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 06-05-2014 |
20140142514 | MEDICAL DELIVERY SYSTEM COMPRISING LOCKING RING WITH L-SHAPED GROOVES - A medical delivery system comprising a container which is adapted to be fastened to a dosing assembly. One of the container and the dosing assembly comprises a rotatable element adapted to cooperate with the other one of the container and the dosing assembly, so as to lock/fasten the container to the dosing assembly. Furthermore, the present invention relates to a container and a dosing assembly for use in the medical delivery system. | 05-22-2014 |
20140142280 | Method of Acylating a Peptide or Protein - A method for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described. | 05-22-2014 |
20140141001 | Anit-Human Interleukin-20 Antibodies - Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders. | 05-22-2014 |
20140112903 | Glycopegylated Factor IX - Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 04-24-2014 |
20140094743 | System for Optimizing a Patient's Drug Dosage Regimen Over Time - A system for optimizing a patient's basal insulin dosage regimen over time, adapted to (a) determine from blood glucose values whether and by how much to vary a patient's present recommended amount of the insulin-containing drug in order to maintain the patient's future blood glucose level measurements within a predefined range, and (b) at the same time display blood glucose value data and the recommended amount data as a function of time. | 04-03-2014 |
20140088005 | DOUBLE-ACYLATED GLP-1 DERIVATIVES - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K | 03-27-2014 |
20140087995 | Polypeptides - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 03-27-2014 |
20140074041 | INJECTION DEVICE INCORPORATING DOSE MONITORING - The present invention relates to an electronically assisted injection device adapted to inject doses of a drug from a held cartridge. The injection device may include a first rotational sensor ( | 03-13-2014 |
20140073892 | GLUCOSE PREDICTOR BASED ON REGULARIZATION NETWORKS WITH ADAPTIVELY CHOSEN KERNELS AND REGULARIZATION PARAMETERS - The invention relates to a method and a device for predicting a glycaemic profile of a subject. A multistage algorithm is employed comprising a prediction setting stage specifying a functional space for the prediction and a prediction execution stage specifying a predicted future glycaemic state of the subject in the functional space as a continuous function of time. | 03-13-2014 |
20140073759 | Purification of Insulin - The present application discloses a chromatographic process for separating protein components of a protein-containing solution, said solution comprising an insulin peptide and one or more di- or polyvalent metal ions, said insulin peptide being capable of self-association and/or structural change in the presence of di- or polyvalent metal ions, said process comprising the steps of: a) applying the protein-containing solution to a column of a chromatographic solid phase material, wherein the loading of the insulin peptide is at least 6.0 g per litre of column volume (g/L | 03-13-2014 |
20140073564 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES - Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. | 03-13-2014 |
20140066482 | Pharmaceutical Formulation Comprising Metformin and Repaglinide - The invention is related to a pharmaceutical composition comprising repaglinide in combination with metformin or a salt thereof in unit dosage form wherein a pre-formulation of the repaglinide has a pH independent dissolution profile and a relative humidity of less than about 25% prior to mixing with the metformin or a salt thereof; and optionally one or more pharmaceutically acceptable excipients and to a method for its preparation. | 03-06-2014 |
20140058218 | APPARATUS AND METHOD FOR DETERMINING A PHYSIOLOGICAL CONDITION - An apparatus for detecting a physiological condition in a person, comprising input means for receiving at least two physiological parameters, processing means for determining, from the received physiological parameters, a result signal indicative of the presence or onset of said physiological condition, and output means for generating an output indicative of the result signal. The apparatus further comprises storage means for storing a look-up table comprising a plurality of entries, each entry corresponding to a pre-calculated probability of the presence or onset of said physiological condition, the pre-calculated probabilities being determined by means of a mathematical process from previously monitored physiological parameters; and the processing means is adapted to process the received at least two physiological parameters to identify one of the plurality of entries of the look-up table, and to determine said result signal from the identified entry of the look-up table. | 02-27-2014 |
20140057848 | FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE - The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake. | 02-27-2014 |
20140056953 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY - The present invention relates to fatty acid acylated amino acids (FA-aa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-aa's. | 02-27-2014 |
20140052068 | MEDICAL INJECTION DEVICE WITH LARGE, MECHANICAL CIPHER DOSE DISPLAY - An injection device is disclosed which comprises a housing (10) with a display for showing the size of a set dose. The display is formed from a number of individual ciphers ( | 02-20-2014 |
20140039409 | Device for Injecting Adjustable Doses of Liquid Drug - The present invention relates to an injection device for administering doses of liquid drug. The injection device comprises a user operable dose adjustment structure configured to adjust, in a prepared state of the device, a dose of liquid drug of a first size to set a dose of a second size. The present injection device is particularly suitable for self-injection of liquid drugs such as insulin for treating diabetes by the user or patient. | 02-06-2014 |
20140031279 | Human Insulin Analogues and Derivatives Comprising Cysteine Substitutions - The present invention relates to human insulin analogues containing a substituting cysteine, to human insulin derivatives containing a PEGylated substituting cysteine and methods of making such. The compounds of the invention may be useful for the treatment of diabetes. | 01-30-2014 |
20140031278 | Novel Glucagon Analogues - The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 01-30-2014 |
20140025018 | NEEDLE MOUNTING SYSTEM AND A METHOD FOR MOUNTING A NEEDLE ASSEMBLY - A needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount. | 01-23-2014 |
20140025014 | Medical Injection Device - The present invention relates to injection devices for injecting a dose of a medicament. The injection device ( | 01-23-2014 |
20140018290 | LEPTIN DERIVATIVES - The invention relates to Leptin derivatives, compositions and therapeutic use there-of. | 01-16-2014 |
20140018286 | AMYLIN ANALOGUES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 01-16-2014 |
20140011732 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use - The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration. | 01-09-2014 |
20140011728 | LONG-ACTING IL-1 RECEPTOR ANTAGONISTS - The present invention relates to IL-1 receptor antagonist compounds, compositions and use thereof as well as methods for preparation thereof. | 01-09-2014 |
20140004198 | GLP-1 PARTICLES AND COMPOSITIONS | 01-02-2014 |
20130345666 | User Interface for Delivery System Providing Dual Setting of Parameters - The invention provides a user input device for operating a drug delivery system is provided, comprising display means adapted to simultaneously display at least two user controllable settings, and user input means allowing a user to simultaneously and directly set each of the simultaneously displayed user controllable settings. By this arrangement a user can effectively and safely enter related information without having to jump between two or more input screens. | 12-26-2013 |
20130345403 | AQUEOUS FACTOR VIII SOLUTION - The present invention relates to methods for stabilizing FVIII in aqueous solutions comprising a relatively high concentration of FVIII. The invention furthermore relates to such aqueous solutions as well as use thereof. | 12-26-2013 |
20130345134 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID - The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine. | 12-26-2013 |
20130344090 | Antibodies Against Tissue Factor Pathway Inhibitor (TFPI) - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting. | 12-26-2013 |
20130344050 | Glycopegylated Factor IX - Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 12-26-2013 |
20130338071 | GLP-1 Agonist and Cardiovascular Complications - Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. | 12-19-2013 |
20130338068 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from | 12-19-2013 |
20130337537 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS - The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention. | 12-19-2013 |
20130336984 | ANTAGONISTIC DR3 LIGANDS - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 12-19-2013 |
20130331320 | FAST-ACTING INSULIN IN COMBINATION WITH LONG-ACTING INSULIN - Insulin preparations comprising a long-acting insulin compound, a fast-acting insulin compound, a nicotinic compound and an amino acid. | 12-12-2013 |
20130330360 | ANTAGONISTIC DR3 LIGANDS - The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR | 12-12-2013 |
20130323259 | IL-21 LIGANDS - The present invention relates to IL-21 ligands binding to a discontinuous epitope on the surface of the IL-21 molecule as well as use thereof. | 12-05-2013 |
20130309239 | ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 11-21-2013 |
20130303999 | Needle Cannula with a Collapse Zone - A metallic cylindrical tubular needle cannula ( | 11-14-2013 |
20130288960 | Double-Acylated GLP-1 Derivatives - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH | 10-31-2013 |
20130281364 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 10-24-2013 |
20130267895 | Piston Rod Foot - The invention relates to a medical drug delivery apparatus which comprises a cartridge ( | 10-10-2013 |
20130266576 | THERAPEUTIC FACTOR VIII ANTIBODIES - The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A. | 10-10-2013 |
20130253699 | REMINDER PROGRAMMING DEVICE AND METHOD - An electronically controlled reminder device is adapted to be set in a programming mode by a user, perform a user-actuated operation, and detect when a user-actuated operation is performed. When in programming mode the device is adapted to record and set reminders in accordance with a detected time pattern of operation(s) of the device, wherein the programming mode is activated for a pre-determined number of operations or for a pre-determined period of time, after which the device automatically returns to the operational mode in which it provides reminders to the user based on the recorded time pattern of operations. Thus, normal use of the device provides automatic programming of the reminder scheme. | 09-26-2013 |
20130253173 | Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor - The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent. | 09-26-2013 |
20130252884 | FGF21 ANALOGUES AND DERIVATIVES - Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described. | 09-26-2013 |
20130251722 | Antibodies Against Tissue Factor Pathway Inhibitor - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy. | 09-26-2013 |
20130251721 | Antibodies Against Tissue Factor Pathway Inhibitor - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy. | 09-26-2013 |
20130243770 | TREATING DIABETES USING INHIBITORS OF IL-1 - The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1. | 09-19-2013 |
20130218093 | Medical Injection Device - The present invention relates to injection devices for injecting a medicament from a cartridge ( | 08-22-2013 |
20130213961 | MEDICAL CONTAINER PROTECTED AGAINST CRACKING - Medical containers made of plastic can be protected against cracking by adding a layer of a poly-paraxylylene structure to said container. | 08-22-2013 |
20130211330 | Medical Injection Device - The present invention relates to medicament injection devices ( | 08-15-2013 |
20130211050 | ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 08-15-2013 |
20130190232 | N-TERMINAL MODIFIED FGF21 COMPOUNDS - Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). | 07-25-2013 |
20130189239 | Conjugated Factor VIII Molecules - The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules. | 07-25-2013 |
20130184350 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 07-18-2013 |
20130183280 | STABILIZED FACTOR VIII VARIANTS - The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules. | 07-18-2013 |
20130178414 | Human Insulin Containing Additional Disulfide Bonds - The present invention is related to human insulin containing additional disulfide bonds and methods of making such. | 07-11-2013 |
20130172695 | Medical Skin Mountable Device and System - A medical device is provided comprising a transcutaneous device unit and a process unit. The transcutaneous device unit may comprise a transcutaneous device for transporting a fluid through a skin portion of a subject, and a mounting surface adapted for application to the skin of the subject. The process unit may comprise a reservoir adapted to contain a fluid drug, the reservoir comprising an outlet means allowing the transcutaneous device to be arranged in fluid communication with an interior of the reservoir, and an expelling assembly for expelling a fluid drug out of the reservoir and through the skin of the subject via the transcutaneous device. The transcutaneous device unit and the process unit further comprise coupling means allowing the reservoir unit to be secured to the transcutaneous device unit in the situation of use. By this arrangement a two-unit system is provided which can be used in a convenient and cost-effective manner. | 07-04-2013 |
20130172247 | Insulin Analogues Containing Additional Disulfide Bonds - The present invention is related to insulin analogues containing additional disulfide bonds and methods of making such. | 07-04-2013 |
20130165370 | Counteracting Drug-Induced Obesity Using GLP-1 Agonists - The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug. | 06-27-2013 |
20130157938 | Insulin Derivatives Containing Additional Disulfide Bonds - The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such. | 06-20-2013 |
20130150799 | Injection Device - The invention concerns an injection device for apportioning set doses of a drug from a reservoir to a subject. The injection device comprises a housing having an interior thread formed as an outwardly pointing thread carried on an upstanding tower centrally located in the pen shaped device. This outwardly pointing thread forms a first thread connection with the interior thread of the rotatable scale drum. The injection device further comprises a driver for moving the piston rod forward when moved axially. The driver operates the piston rod through a second thread connection having a pitch different than the first thread connection. | 06-13-2013 |
20130150559 | NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF - Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 06-13-2013 |
20130143803 | Process for the Preparation of Insulin-Zinc Complexes - The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation. | 06-06-2013 |
20130143798 | NOVEL GLUCAGON ANALOGUES - The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 06-06-2013 |
20130142804 | Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor - The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent. | 06-06-2013 |
20130137638 | CONJUGATED FACTOR VIII MOLECULES - The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules. | 05-30-2013 |
20130137157 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA - The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention. | 05-30-2013 |
20130136733 | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative - The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein. | 05-30-2013 |
20130123685 | ELECTRONICALLY MONITORED INJECTION DEVICE - Medical injection advice adapted for operating in a dose setting mode and in a dose administration mode, comprising a dosing actuator ( | 05-16-2013 |
20130105345 | Two-Part Hinged Needle Magazine | 05-02-2013 |
20130096055 | LONG-ACTING Y2 RECEPTOR AGONISTS - The present invention relates to PYY derivatives comprising a serum albumin binding side chain, wherein said derivative has a half-life of at least 7 hours as determined by Assay (IV) described herein as well as compositions comprising said derivative and its use in therapy. | 04-18-2013 |
20130095555 | Hyperglycosylated Human Coagulation Factor IX - The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia. | 04-18-2013 |
20130079728 | INJECTION DEVICE - A medication dispensing device with a housing and a member wherein the member is moveable in a distal direction is useful in delivering medication to a patient. A fluid container can be used with the device and often has a moveable piston at one end and an outlet at the other. The member receives a force from a user and drives the piston in the distal direction to expel medication. A intermediate system is disposed between the member and the piston including a gear set that has a pinion in meshed engagement with a rack. The system allows the member to move a greater distance than the piston moves thereby increasing the force on the piston. | 03-28-2013 |
20130079278 | Novel Glucagon Analogues - The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 03-28-2013 |
20130071383 | SELECTIVE MODIFICATION OF PROTEINS - A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein. | 03-21-2013 |
20130059781 | Long-Acting Gastrin Derivatives - The present invention relates to gastrin derivatives comprising gastrin or an analogue or fragment thereof and a derivatisation group and therapeutic use thereof. | 03-07-2013 |
20130059770 | POLYPEPTIDES - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 03-07-2013 |
20130058999 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN PEPTIDES - The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such. | 03-07-2013 |
20130053315 | NOVEL GLP-1 DERIVATIVES - Novel polypeptide derivatives having protracted profile of action. | 02-28-2013 |
20130052192 | Activatable Constructs - The current invention relates to a construct, a polynucleotide that encodes said construct and a cell that expresses said construct. Furthermore, the current invention relates to the use of said construct for the treatment of bleedings and their associated co-morbidities and to a method of treatment of bleedings, inflammation and metastasis of cancer cells. | 02-28-2013 |
20130040889 | Factor VIII Fusion Protein - The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain. | 02-14-2013 |
20130040888 | Factor VIII Molecules With Reduced VWF Binding - The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group. | 02-14-2013 |
20130040884 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG - Novel polypeptide derivatives having protracted profile of action. | 02-14-2013 |
20130040877 | LONG-ACTING Y2 RECEPTOR AGONISTS - The present invention relates to PYY analogues or derivatives thereof comprising at least one alteration selected from the group consisting of substitutions, insertions, deletions and modifications and optionally a serum albumin binding side chain comprising an alkyl chain with at least 14 carbon atoms. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y2 receptor modulation. | 02-14-2013 |
20130039923 | ANTI-HUMAN INTERLEUKIN-20 ANTIBODIES - Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders. | 02-14-2013 |
20130035641 | Injection Device with Torsion Spring and Rotatable Display - The present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof. | 02-07-2013 |
20130035285 | NOVEL GLUCAGON ANALOGUES - The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 02-07-2013 |
20130030053 | NOVEL NIDDM REGIMEN - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 01-31-2013 |
20130028907 | Stable Antibody Containing Compositions - The invention relates to stable and low viscous (<50 cP) protein containing compositions, in particular, but not exclusively stable antibody containing compositions and to the use of said stable proteins in therapy, in particular for the subcutaneous delivery of said stable protein. | 01-31-2013 |
20130028901 | NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 01-31-2013 |
20130012684 | Purification Method - The present invention provides a method for purification of a protein that is conjugated to an albumin binding moiety from a mixture comprising (i) said protein in said conjugated form and (ii) said protein in a form that is not conjugated to said albumin-binding moiety, the method comprising: (a) providing a solid support comprising a substance capable of specifically binding to the albumin binding moiety; (b) contacting said solid support of (a) with said mixture comprising protein and conjugated protein under suitable conditions for binding of the albumin binding moiety to the substance as defined in (a); and (c) eluting components bound to the solid support. | 01-10-2013 |
20130012432 | Peptides for Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 01-10-2013 |
20130012427 | POLYPEPTIDES - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 01-10-2013 |
20130005951 | PROCESS FOR PREPARING FGF21 WITH LOW DEGREE OF O-GLYCOSYLATION - Expression of FGF21 in a | 01-03-2013 |
20130005646 | POLYPEPTIDES - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 01-03-2013 |
20130004524 | Conjugated Proteins - The present invention relates to modified therapeutic proteins, such as e.g. coagula-tion factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group. | 01-03-2013 |
20130004514 | THERAPEUTIC ANTIBODIES - The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders. | 01-03-2013 |
20120322976 | Preparative RP-HPLC Method For Purifying Peptides - A method for separating on a RP-HPLC system a polypeptide of interest from at least one unwanted component is described, wherein at least one of the elution steps is performed at or in close proximity to the pl value of the peptide of interest. | 12-20-2012 |
20120322738 | CONJUGATED FVIII VARIANTS - The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof. | 12-20-2012 |
20120322733 | NOVEL PEPTIDYL ALPHA-HYDROXYGLYCINE ALPHA-AMIDATING LYASES - The present patent application concerns an enzyme capable of catalysing the conversion of a α-hydroxyglycine to an α-amide and the use of such enzymes for producing a C-terminal α-amidated peptide. | 12-20-2012 |
20120295847 | Acylated GLP-1 Compounds - Protracted GLP-1 compounds and therapeutic uses thereof. | 11-22-2012 |
20120295836 | GLP-I Agonist And Cardiovascular Complications - Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. | 11-22-2012 |
20120289453 | NOVEL GLP-1 COMPOUNDS - Novel GLP-1 compounds and their therapeutic use. | 11-15-2012 |
20120283170 | Acylated Exendin-4 Compounds - This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such. | 11-08-2012 |
20120282653 | METHOD FOR MAKING POLYPEPTIDES - The invention provides an improved method for producing polypeptides with a C-terminal glycine in a yeast transformant being characterized in having a non functional KEX1 gene. The method is in particular well suited to produce polypeptides with an aromatic amino acid residue attached to the C-terminal glycine. The yeast strain may have further non-functional protease genes selected from PEP4, YPS1, MKCI, YPS3, YPS5, YPS6, YPS7, PRB1, STE13 and KEX2. | 11-08-2012 |
20120277724 | Disposable Double Point Injection Needle and an Insulin Injection System Comprising a Disposable Double Point Injection Needle - A disposable double pointed injection needle has a needle hub to which a thin needle cannula is permanently fastened and which needle hub can be mounted on to a syringe comprising a dose setting and injection mechanism and a cartridge containing a liquid medicine to be injected subcutaneously into a human body. The needle hub is provided with a safety shield guided on the needle hub. The safety shield is urged in a direction away from the needle hub by a spring located between the needle hub and the safety shield. After injection the shield is moved away from the needle hub by the spring and locked in an irreversible position where the safety shield covers the needle cannula and prevents accidental needle stick injuries. | 11-01-2012 |
20120271249 | METHOD FOR CHEMICAL ETCHING OF A NEEDLE CANNULA - A regular metallic, cylindrical tubular needle cannula ( | 10-25-2012 |
20120245085 | Pharmaceutical Solution of Non Covalently Bound Albumin and Acylated Insulin - If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection. | 09-27-2012 |
20120245083 | Derivatives of CGRP - Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments. | 09-27-2012 |
20120237510 | Anti-NKG2A Antibodies and Uses Thereof - Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described. | 09-20-2012 |
20120232474 | DRUG DELIVERY SYSTEM AND DEVICE WITH CAP FUNCTION - A system comprising first and second drug delivery devices ( | 09-13-2012 |
20120226235 | METHOD AND ARRANGEMENT FOR REDUCING AIR BUBBLES IN FLUIDIC SYSTEM - The invention provides a fluidic system ( | 09-06-2012 |
20120225810 | PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES - The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation. | 09-06-2012 |
20120220517 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 08-30-2012 |
20120215162 | Injection Device Comprising An Optical Sensor - The present invention relates to an injection device comprising an optically-based sensor for determining the position or setting of a dose setting member arranged to set a dose to be injected from the injection device. In particular, the present invention relates to an injection device comprising a rotatably mounted member having a plurality of optically coded paths arranged on an outer surface thereof. The rotatably mounted member is operatively connected to the dose setting member and is adapted to rotate with the dose setting member. | 08-23-2012 |
20120208749 | Insulin derivatives - The present invention is related to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of B chain or to an ε-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond which side chain comprises one or more residues of ethyleneglycol, propyleneglycol and/or butyleneglycol containing independently at each termini a group selected from —NH | 08-16-2012 |
20120203185 | Cartridge And Medical Delivery System Accommodating Such Cartridge - A cartridge having a distal end provided with a mechanical coding. The coding has the form of a circular protrusion where the circular outer diameter is dedicated a specific concentration of insulin contained in the cartridge. The distal end of the cartridge is fitted in to a circular contour in the housing. The outer diameter of the protrusion on the distal end of the cartridge is chosen as a larger diameter for a higher concentration of insulin. In this way only a cartridge containing the correct concentration or a lower concentration fits into a delivery system designed for a specific concentration of insulin. | 08-09-2012 |
20120202881 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 08-09-2012 |
20120196800 | STABLE NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN - The invention describes a non-aqueous liquid pharmaceutical composition comprising at least one lipid and at least one insulin. Also described is a method of producing a pharmaceutical composition comprising a lipid and a method of purifying a lipid, a cosolvent, a surfactant or a pharmaceutical composition comprising a lipid. | 08-02-2012 |
20120195888 | Humanized Antibodies Against Human Interferon-Alpha - The present invention provides humanized anti-human IFN-α monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof. | 08-02-2012 |
20120191046 | DRUG DELIVERY DEVICE WITH CAP FUNCTIONS FOR NEEDLE ASSEMBLY - Drug delivery system comprising a main portion with a cap as well as a needle assembly with a needle mounted in a hub and a needle cap releasably mountable on the hub to cover the needle. The cap comprises gripping means reversibly operatable between a first condition in which there is no gripping engagement between the mounted cap portion and the needle cap, this allowing the cap portion to be removed from the main portion without removing the needle cap from the hub, and a second condition in which the cap portion grippingly can engage the needle cap of a needle assembly, this allowing the needle cap to be removed from the hub together with the cap. The cap further comprises user actuation means for operating the gripping means between the two conditions. | 07-26-2012 |
20120184917 | FROST PROTECTED INJECTION DEVICE - The invention relates to an injection device ( | 07-19-2012 |
20120184487 | INSULIN DERIVATIVES - The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue. | 07-19-2012 |
20120178908 | TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS - The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention. | 07-12-2012 |
20120172811 | AUTO-PRIMING INJECTION DEVICE - The invention relates to an injection device ( | 07-05-2012 |
20120172300 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) - The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants. | 07-05-2012 |
20120172298 | GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 - The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21) compound and a Glucagon-Like Peptide 1 (GLP-1) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of beta cells ex vivo in the presence of free fatty acids, on caspase activity of beta cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db/db mice in vivo. | 07-05-2012 |
20120165745 | CAP LOCK - A needle assembly for a medical device comprising a needle cannula which is mounted in a hub connectable to a medical device, and which needle assembly comprises releasable locking means which co-operates with the connection means of the hub such that the needle cap is locked to the hub when the releasable locking means is not released. Once the locking means is released by activation of the connection means, the needle cap is unlocked from the hub. The activation of the locking means is preferably done automatically when the needle assembly is attached to the medical device. | 06-28-2012 |
20120165375 | Urea Glucokinase Activators - This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such. | 06-28-2012 |
20120158424 | SYSTEM AND METHOD FOR ASSISTING IN THE HOME TREATMENT OF A MEDICAL CONDITION - An interactive home treatment system and method is disclosed. Patient data is collected via a handheld device and stored in a database. The data may be related to self-treatments, symptoms, or patient behavior. The data are analyzed with an analytic tool and the analysis is used to generate a message that is transmitted to a treating health care professional or to the patient, or both. A set of predetermined rules may be applied to the data. The rules may be modified by the treating health care professional, the patient, or both. The handheld device, the database, and the analytic tool may be web-enabled to facilitate communication from virtually anywhere. | 06-21-2012 |
20120157932 | INJECTION DEVICE - An injection device for injection of set doses of medicine from a cartridge has a nut that is screwed up along a threaded piston rod during a dose setting operation. The nut is screwed along the piston rod by rotating a dose setting member. A rotational coupling mechanism includes an axially displaceable coupling member which is rotated as a function of axial displacement. During dose setting, the nut is allowed to rotate relative to the coupling member. During injection, the coupling member is rotationally locked to the nut. This provides a dose setting and injection mechanism wherein the nut member is both rotated during dose setting and during injection. | 06-21-2012 |
20120149868 | PURIFICATION OF PEPTIDES PREPARED BY SOLID PHASE SYNTHESIS - The invention relates to an effective process for purifying a peptide which has been prepared by solid phase peptide synthesis. Also encompassed by the invention is a kit comprising reagents for said process and the purified peptide obtained by said process. | 06-14-2012 |
20120143149 | Needle Mounting System and a Method for Mounting a Needle Assembly - A needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount. | 06-07-2012 |
20120135920 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 05-31-2012 |
20120135519 | INDUCED DERIVATION OF SPECIFIC ENDODERM FROM hPS CELL-DERIVED DEFINITIVE ENDODERM - The present invention relates to a method to control differentiation of human pluripotent stem cells, including human balstocyst derived stem (hBS) cells and to obtain specific endoderm cells. In particular, present invention relates to the use of FGF2 as the key factor in a specific concentration to control differentiation of definitive endoderm cells derived from hPS cells to specific endoderm cells. The invention also provides methods of obtaining endoderm cells comprising the use of FGFR and activation of the MAPK signalling pathway. | 05-31-2012 |
20120132572 | SPHERICAL ENCODED BEADS - The present application discloses spherical polymer bead comprising embedded therein an ultrasonic identification chip, said chip comprising one or more resonator cavities, the dimensions of each of the one or more resonator cavities giving rise to an ultrasonic resonance frequency of 20 kHz or more. The application also discloses a bead sorting apparatus equipped with at least one ultrasonic transmitter and at least one ultrasonic receiver, and a method of measuring the ultrasonic code of an ultrasonic encoded bead using the bead sorting apparatus. | 05-31-2012 |